The company has not filed an annual or quarterly report since its FY2017 10-K, filed Feb 14, 2018. Its latest SEC filing is a SC 13G/A from Apr 10, 2018.
10-K for FY2017, filed Feb 14, 2018
The sections below describe the company as of the FY2017 annual report.
Sells longer-lasting clotting-factor therapies for hemophilia A and B to specialty pharmacies, treatment centers and hospitals, and develops treatments for other rare blood diseases.
10-K for FY2017, filed Feb 14, 2018Bioverativ is a global biopharmaceutical company focused on the discovery, research, development and commercialization of innovative…View ↗
Lead in Hemophilia. We have two marketed products, ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX…View ↗
We are engaged in discovery, preclinical, and clinical programs focused on advancing new technologies for the treatment of hemophilia and…View ↗
We have our own direct sales force. Our products are distributed to and through specialty pharmacies, hemophilia treatment centers, public…View ↗
Bioverativ sells its hemophilia products to specialty pharmacies, treatment centers, hospitals and specialty distributors, with sales counted when delivery occurs. It also earns revenue from supplying products to Sobi and royalties on Sobi's sales.
10-K for FY2017, filed Feb 14, 2018The company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has…View ↗
We sell mainly to specialty pharmacies, hemophilia treatment centers, public and private hospitals and independent specialty distributors.…View ↗
Our revenues are primarily derived from sales of ELOCTATE and ALPROLIX in the United States, Japan and Canada. We also earn revenue from…View ↗
$1.2B
10-K for FY2017, filed Feb 14, 2018
$1.2B ↗
Bioverativ uses its own sales force and distributes products through specialty pharmacies, treatment centers and hospitals, as well as independent distributors. It sells directly in Japan; Sobi commercializes products in its territory.
10-K for FY2017, filed Feb 14, 2018We have our own direct sales force. Our products are distributed to and through specialty pharmacies, hemophilia treatment centers, public…View ↗
In the United States, third parties warehouse and ship our products through their distribution centers. These centers are generally stocked…View ↗
We use and expect to continue to use a variety of collaboration, distribution and other marketing arrangements with one or more third…View ↗
Yes. It kept 30 cents of every revenue dollar as net income in FY2017 and turned 49 cents into free cash flow.
10-K for FY2017, filed Feb 14, 2018
10-K for FY2017, filed Feb 14, 2018
$447.2MView ↗
10-K for FY2017, filed Feb 14, 2018
$355.6MView ↗
10-K for FY2017, filed Feb 14, 2018
$577.6MView ↗
8-K, filed Mar 8, 2018
As a result of the Purchaser’s acceptance for payment of all Shares that were validly tendered and not validly withdrawn in accordance with…View ↗
Grew.
Revenue grew 2.1x in 2 years, from $560.3M in FY2015 to $1.2B in FY2017, about 44% a year.
10-K for FY2017, filed Feb 14, 2018
Competes with Shire, CSL Behring, Genentech, Bayer, Novo Nordisk, Octapharma, Pfizer, Sobi, and Aptevo
10-K for FY2017, filed Feb 14, 2018ADVATE® (Antihemophilic Factor (Recombinant))—ShireView ↗
Loading...
